Selskabets formål er at drive handel, industri og finansiering samt anden dermed beslægtet virksomhed, herunder at drive virksomhed gennem datterselskaber.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 2.5 mia. | 48 mio. | 1.5 mia. | 577.6 mio. | 106 | |
CVR: 27744532
Secondary names: DURASCAN A/S, DURASCAN MEDICAL PRODUCTS A/S, HEXAL SCANDINAVIA A/S
Previous names: DURASCAN MEDICAL PRODUCTS A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Lawrence Edward Mead joined the board
Kerstin Elisabeth Jarvheden left the board
Companies in the same industry and area
CVR 41722460
CVR 39371049
CVR 39503778
CVR 40873309
CVR 31774284
SANDOZ A/S demonstrates a solid financial health with a consistent upward trajectory in revenue, reaching 2.52 billion DKK in 2024, up from 2.29 billion DKK in 2023. However, profit has decreased from 68.5 million DKK in 2023 to 48 million DKK in 2024, indicating potential margin pressures. The company's equity has improved significantly, standing at 577.6 million DKK, reflecting a strong capital position within the pharmaceutical wholesale industry. Despite the recent dip in profitability, SANDOZ A/S maintains a robust revenue growth trend, positioning itself favorably among competitors.
AI-generated summary
companydata.dk